Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma - Nagai - European Journal of Haematology - Wiley Online Library
Links shared publicly online about this topic.
- 732total visits
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma - Nagai - European Journal of Haematology - Wiley Online Library
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma - Nagai - European Journal of Haematology - Wiley Online Library
View full resource at onlinelibrary.wiley.com
Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Rituxan, MabThera
Most Recently Shared on November 12, 2010 at 8:03 pm By:
Cladribine combined with rituximab (Râ€*2â€*CdA) therapy is an effective salvage therapy in relapsed or refracto... http://bit.ly/ar8rPO
Advertisement
